Cargando…

Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST

Natural killer (NK) cells are currently used in clinical trials to treat tumors. However, such therapies still suffer from problems such as donor variability, reproducibility, and more, which prevent a wider use of NK cells therapeutics. Here we show a potential immunotherapy combining NK cell-media...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotzur, Rebecca, Stein, Natan, Kahlon, Shira, Berhani, Orit, Isaacson, Batya, Mandelboim, Ofer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440710/
https://www.ncbi.nlm.nih.gov/pubmed/37609636
http://dx.doi.org/10.1016/j.isci.2023.107284
_version_ 1785093212198666240
author Kotzur, Rebecca
Stein, Natan
Kahlon, Shira
Berhani, Orit
Isaacson, Batya
Mandelboim, Ofer
author_facet Kotzur, Rebecca
Stein, Natan
Kahlon, Shira
Berhani, Orit
Isaacson, Batya
Mandelboim, Ofer
author_sort Kotzur, Rebecca
collection PubMed
description Natural killer (NK) cells are currently used in clinical trials to treat tumors. However, such therapies still suffer from problems such as donor variability, reproducibility, and more, which prevent a wider use of NK cells therapeutics. Here we show a potential immunotherapy combining NK cell-mediated tumor eradiation and long non-coding (lnc) RNAs. We overexpressed the interferon (IFN) [Formula: see text] secretion-enhancing lncRNA nettoie Salmonella pas Theiler’s (NeST) in the NK cell-like cell line YTS. YTS cells express the co-stimulatory receptor 2B4 whose main ligand is CD48. On YTS cells, 2B4 functions by direct activation. We showed that NeST overexpression in YTS cells resulted in increased IFN [Formula: see text] release upon interaction with CD48 (selectively enhanced (se)YTS cells). Following irradiation, the seYTS cells lost proliferation capacity but were still able to maintain their killing and IFN [Formula: see text] secretion capacities. Finally, we demonstrated that irradiated seYTS inhibit tumor growth in vivo. Thus, we propose seYTS cells as off-the-shelve therapy for CD48-expressing tumors.
format Online
Article
Text
id pubmed-10440710
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104407102023-08-22 Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST Kotzur, Rebecca Stein, Natan Kahlon, Shira Berhani, Orit Isaacson, Batya Mandelboim, Ofer iScience Article Natural killer (NK) cells are currently used in clinical trials to treat tumors. However, such therapies still suffer from problems such as donor variability, reproducibility, and more, which prevent a wider use of NK cells therapeutics. Here we show a potential immunotherapy combining NK cell-mediated tumor eradiation and long non-coding (lnc) RNAs. We overexpressed the interferon (IFN) [Formula: see text] secretion-enhancing lncRNA nettoie Salmonella pas Theiler’s (NeST) in the NK cell-like cell line YTS. YTS cells express the co-stimulatory receptor 2B4 whose main ligand is CD48. On YTS cells, 2B4 functions by direct activation. We showed that NeST overexpression in YTS cells resulted in increased IFN [Formula: see text] release upon interaction with CD48 (selectively enhanced (se)YTS cells). Following irradiation, the seYTS cells lost proliferation capacity but were still able to maintain their killing and IFN [Formula: see text] secretion capacities. Finally, we demonstrated that irradiated seYTS inhibit tumor growth in vivo. Thus, we propose seYTS cells as off-the-shelve therapy for CD48-expressing tumors. Elsevier 2023-07-05 /pmc/articles/PMC10440710/ /pubmed/37609636 http://dx.doi.org/10.1016/j.isci.2023.107284 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kotzur, Rebecca
Stein, Natan
Kahlon, Shira
Berhani, Orit
Isaacson, Batya
Mandelboim, Ofer
Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST
title Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST
title_full Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST
title_fullStr Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST
title_full_unstemmed Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST
title_short Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST
title_sort eradication of cd48-positive tumors by selectively enhanced yts cells harnessing the lncrna nest
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440710/
https://www.ncbi.nlm.nih.gov/pubmed/37609636
http://dx.doi.org/10.1016/j.isci.2023.107284
work_keys_str_mv AT kotzurrebecca eradicationofcd48positivetumorsbyselectivelyenhancedytscellsharnessingthelncrnanest
AT steinnatan eradicationofcd48positivetumorsbyselectivelyenhancedytscellsharnessingthelncrnanest
AT kahlonshira eradicationofcd48positivetumorsbyselectivelyenhancedytscellsharnessingthelncrnanest
AT berhaniorit eradicationofcd48positivetumorsbyselectivelyenhancedytscellsharnessingthelncrnanest
AT isaacsonbatya eradicationofcd48positivetumorsbyselectivelyenhancedytscellsharnessingthelncrnanest
AT mandelboimofer eradicationofcd48positivetumorsbyselectivelyenhancedytscellsharnessingthelncrnanest